Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives

M. Svajdova, P. Dubinsky, T. Kazda, B. Jeremic

. 2022 ; 14 (21) : . [pub] 20221101

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031389

Over the last two decades, human papillomavirus (HPV) has caused a new pandemic of cancer in many urban areas across the world. The new entity, HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), has been at the center of scientific attention ever since, not only due to its distinct biological behavior, but also because of its significantly better prognosis than observed in its HPV-negative counterpart. The very good treatment outcomes of the disease after primary therapy (minimally-invasive surgery, radiation therapy with or without chemotherapy) resulted in the creation of a separate staging system, reflecting this excellent prognosis. A substantial proportion of newly diagnosed HPV-driven OPSCC is diagnosed in stage I or II, where long-term survival is observed worldwide. Deintensification of the primary therapeutic methods, aiming at a reduction of long-term toxicity in survivors, has emerged, and the quality of life of the patient after treatment has become a key-point in many clinical trials. Current treatment recommendations for the treatment of HPV-driven OPSCC do not differ significantly from HPV-negative OPSCC; however, the results of randomized trials are eagerly awaited and deemed necessary, in order to include deintensification into standard clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031389
003      
CZ-PrNML
005      
20230127131142.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14215385 $2 doi
035    __
$a (PubMed)36358801
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Svajdova, Michaela $u Department of Radiation and Clinical Oncology, General Hospital Rimavska Sobota, 979 01 Rimavska Sobota, Slovakia $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 602 00 Brno, Czech Republic $1 https://orcid.org/0000000263723295
245    10
$a Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives / $c M. Svajdova, P. Dubinsky, T. Kazda, B. Jeremic
520    9_
$a Over the last two decades, human papillomavirus (HPV) has caused a new pandemic of cancer in many urban areas across the world. The new entity, HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), has been at the center of scientific attention ever since, not only due to its distinct biological behavior, but also because of its significantly better prognosis than observed in its HPV-negative counterpart. The very good treatment outcomes of the disease after primary therapy (minimally-invasive surgery, radiation therapy with or without chemotherapy) resulted in the creation of a separate staging system, reflecting this excellent prognosis. A substantial proportion of newly diagnosed HPV-driven OPSCC is diagnosed in stage I or II, where long-term survival is observed worldwide. Deintensification of the primary therapeutic methods, aiming at a reduction of long-term toxicity in survivors, has emerged, and the quality of life of the patient after treatment has become a key-point in many clinical trials. Current treatment recommendations for the treatment of HPV-driven OPSCC do not differ significantly from HPV-negative OPSCC; however, the results of randomized trials are eagerly awaited and deemed necessary, in order to include deintensification into standard clinical practice.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Dubinsky, Pavol $u Department of Radiation Oncology, East Slovakia Oncology Institute, 040 01 Kosice, Slovakia $u Faculty of Health, Catholic University Ruzomberok, 034 01 Ruzomberok, Slovakia
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 602 00 Brno, Czech Republic $1 https://orcid.org/0000000172888975
700    1_
$a Jeremic, Branislav $u School of Medicine, University of Kragujevac, 340 00 Kragujevac, Serbia
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 21 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36358801 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131134 $b ABA008
999    __
$a ok $b bmc $g 1889481 $s 1182722
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 14 $c 21 $e 20221101 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace